New Pill Offers Hope for Advanced Pancreatic Cancer Patients

A new medication shows promise for patients with advanced pancreatic cancer, according to a report presented on Sunday. While not a cure, this development brings needed advancements for a cancer that ranks among the deadliest. Dr. Zev Wainberg of UCLA, a leader of this study, highlighted its significance.

The drug, named daraxonrasib, targets a protein mutation driving tumor growth in over 90% of pancreatic cancer cases. Historically, this target was difficult to treat. The pill nearly doubled survival times for patients in the trial who were no longer responding to existing treatments. Those taking the medication lived an average of 13.2 months versus 6.7 months with chemotherapy, marking a notable improvement.

These findings appeared in the New England Journal of Medicine and were shared at the American Society for Clinical Oncology meeting in Chicago. Dr. Rachna Shroff from the University of Arizona Cancer Center expressed emotional reactions to the results, noting the drug’s enduring benefits for patients.

Despite the drug’s effects diminishing over time, patients continued using it longer than chemotherapy, experiencing less pain and improved life quality. Many participants were still on the drug when the study concluded, leading researchers to suggest the survival benefit could grow with ongoing monitoring.

Dr. Brian Wolpin from Dana-Farber Cancer Institute proposed this drug as a new care standard for treated metastatic pancreatic cancer. There’s potential for its use earlier in treatment, possibly enabling more patients to be eligible for surgery.

Revolution Medicines funded the study, and the FDA plans to fast-track the drug’s review. Eligible patients may access the drug under an ‘expanded access’ program. Former U.S. Senator Ben Sasse, who uses the medication, mentioned experiencing less pain, raising public awareness of the drug.

Pancreatic cancer proves challenging because early detection is rare. The American Cancer Society estimates 67,000 new U.S. cases this year, with over 52,000 fatalities. The five-year survival rate remains at 13%. Unlike other cancers that benefit from diverse treatments, pancreatic cancer poses significant obstacles.

The drug addresses KRAS mutations crucial to the cancer’s progression, historically seen as ‘undruggable.’ Revolution Medicines employs a molecular interaction with KRAS subtypes, with potential for further research on specific subtypes. Dr. Andrew Coveler of the Fred Hutchinson Cancer Center noted the innovative mechanism underlying this treatment.

Potential developments include drugs targeting KRAS subtypes and vaccines aiming to prevent recurrence after surgery. The discovery marks a potential turning point, sparking hope among specialists not involved in the research.

The Associated Press Health and Science Department receives support from external foundations, but maintains full editorial independence. This support contributes to ongoing health reporting initiatives.